Breaking News Instant updates and real-time market news.

TSLA

Tesla

$801.69 /

-32.13 (-3.85%)

14:04
02/25/20
02/25
14:04
02/25/20
14:04

NTSB finds Tesla driver in Autopilot crash was playing a phone game, AP says

The National Transportation Safety Board said that the driver of a Tesla vehicle who died in a Silicon Valley crash two years ago was playing a video game on his smartphone at the time of the collision, the Associated Press reports. At a hearing on the matter, NTSB chair Robert Sumwalt said that partially automated driving systems, including Tesla's Autopilot, cannot drive themselves, though drivers continue to use them without watching the road, the report says. Reference Link

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

TSLA Tesla
$801.69 /

-32.13 (-3.85%)

02/25/20
Fly Intel: Top five analyst downgrades
02/24/20 Jefferies
Tesla downgraded to Hold from Buy at Jefferies
02/19/20 Piper Sandler
Piper boosts Tesla target to $928 from $729 after installing solar system
02/18/20 Morgan Stanley
Tesla price target raised to $500 from $360 at Morgan Stanley

TODAY'S FREE FLY STORIES

Conference/Events
Upland Software participates in a conference call with Jefferies » 17:02
03/28/20
03/28
17:02
03/28/20
17:02
UPLD

Upland Software

$24.51 /

-1.81 (-6.88%)

Software & Internet…

Software & Internet Analyst Thill holds a conference call with Chairman & CEO McDonald and CFO Hill on April 1 at 10 am hosted by Jefferies.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Jefferies software/Internet analyst to hold an analyst/industry conference call » 16:55
03/28/20
03/28
16:55
03/28/20
16:55

Software and Internet…

Software and Internet Analyst Thill, along with Microsoft Cloud Expert Mary Jo Foley, discusses COVID-19 trends on the industry on an Analyst/Industry conference call to be held on March 31 at 11 am.

Conference/Events
Teck Resources to host conference call » 16:46
03/28/20
03/28
16:46
03/28/20
16:46
TECK

Teck Resources

$6.51 /

-1.025 (-13.61%)

Conference call to…

Conference call to provide the Company's QB2 Project Update and Annual Business Review will be held on April 1 at 1 pm. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Sintx Technologies to host business news update conference call » 16:34
03/28/20
03/28
16:34
03/28/20
16:34
SINT

Sintx Technologies

$0.43 /

+0.0922 (+27.29%)

Business news update…

Business news update conference call will be held on April 2 at 11 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Neonode to host conference call » 16:30
03/28/20
03/28
16:30
03/28/20
16:30
NEON

Neonode

$1.57 /

-0.08 (-4.85%)

Management to hold a…

Management to hold a strategic review conference call on April 2 at 7 am. Webcast Link

Conference/Events
Sanderson Farms to host conference call » 16:21
03/28/20
03/28
16:21
03/28/20
16:21
SAFM

Sanderson Farms

$119.18 /

-5.08 (-4.09%)

Conference call to…

Conference call to provide an update on the Company's response to COVID-19 and current poultry market conditions will be held on April 2 at 11 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
GM agrees to $120M settlement to resolve ignition lawsuits, Bloomberg says » 12:42
03/28/20
03/28
12:42
03/28/20
12:42
GM

General Motors

$21.37 /

-1.17 (-5.19%)

General Motors agreed to…

General Motors agreed to a $120M settlement over faulty ignition switches that allegedly caused cars to stall and air bags to deploy, in some cases triggering fatal accidents, Bloomberg's Robert Burnson reports. The deal, which must be approved by a judge, would resolve hundreds of lawsuits filed before the automaker sought bankruptcy protection in 2009, the author notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
SoftBank's OneWeb files for bankruptcy, Bloomberg reports » 12:40
03/28/20
03/28
12:40
03/28/20
12:40
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

OneWeb filed for…

OneWeb filed for bankruptcy, becoming one of the first companies backed by SoftBank to seek court protection from its creditors after high costs and stiff competition led to a cash crunch, Bloomberg's Rick Green and Eliza Ronalds-Hannon report. The company listed liabilities and assets of more than $1B each in its Chapter 11 petition in U.S. Bankruptcy Court in White Plains, New York. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Ocado buys 100,000 coronavirus testing kits from staff, Telegraph says » 10:59
03/28/20
03/28
10:59
03/28/20
10:59
OCDGF

Ocado Group

$0.00 /

+ (+0.00%)

Ocado has bought 100,000…

Ocado has bought 100,000 coronavirus testing kits to keep as many employees as possible in warehouses and on the road delivering food, The Telegraph's Phoebe Southworth, Tony Diver, Charles Hymas and Jack Hardy report. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Amgen announces results from Phase 3B study of Repatha » 10:17
03/28/20
03/28
10:17
03/28/20
10:17
AMGN

Amgen

$198.49 /

+ (+0.00%)

Amgen announced positive…

Amgen announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK study evaluating the efficacy and safety of Repatha in patients who are human immunodeficiency virus-positive and have high low-density lipoprotein cholesterol despite stable background lipid-lowering therapy. The study demonstrated that treatment with Repatha significantly reduced LDL-C. Results from the double-blind 24-week study show that in people living with HIV with hypercholesterolemia or mixed dyslipidemia, monthly treatment with Repatha reduced LDL-C by 56.9% from baseline compared to placebo, meeting its primary endpoint.1 Patients treated with Repatha also demonstrated improved secondary outcomes versus placebo with 71.9% of patients achieving an LDL-C reduction of more than or equal to 50% from baseline and 65.4% of patients achieving an LDL-C of less than 70 mg/dL. No new safety concerns were identified in the BEIJERINCK trial. The subject incidence of treatment-emergent adverse events was comparable among both groups. The Phase 3b BEIJERINCK study is part of Amgen's PROFICIO program of clinical and real-world evidence studies investigating the impact of Repatha and examining the use of lipid-lowering therapies across different patient populations. To date, the PROFICIO program consists of 35 clinical trials including more than 41,000 patients worldwide and more than 80 real-world evidence studies.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Edwards Lifesciences pauses enrollments in pivotal Mitral, Tricuspid trials » 10:14
03/28/20
03/28
10:14
03/28/20
10:14
EW

Edwards Lifesciences

$198.40 /

-1.49 (-0.75%)

Edwards Lifesciences…

Edwards Lifesciences announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response around the globe. Edwards is coordinating with the trials' clinical investigators, and the decision to resume enrollments in the trials will be made in consultation with each investigator and hospital at the time when their clinicians' and patients' needs can be better served.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Merck presents results from VICTORIA trial evaluating vericiguat » 10:11
03/28/20
03/28
10:11
03/28/20
10:11
MRK

Merck

$71.62 /

-1.77 (-2.41%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Merck (MRK) announced the…

Merck (MRK) announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered soluble guanylate cyclase stimulator being developed to treat patients with heart failure with reduced ejection fraction and following a worsening event. VICTORIA is the first contemporary outcomes study focused exclusively on symptomatic chronic heart failure patients following a worsening event. Vericiguat is being jointly developed with Bayer (BAYRY). Patients enrolled in VICTORIA were at high risk of hospitalization and cardiovascular death following a recent heart failure decompensation. Vericiguat, when given in combination with available heart failure therapies, met the primary efficacy endpoint of reducing the risk for the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction, compared to placebo. A hazard ratio of 0.90 in this high risk population translated into a clinically relevant 4.2/100 patient-years absolute reduction in event rate. Based on this absolute risk reduction, the number needed to treat with vericiguat for one year to prevent a primary outcome event is approximately 24 patients. The safety profile of vericiguat was consistent with that reported in previous studies. Merck and Bayer plan to share VICTORIA data with regulatory authorities worldwide.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AstraZeneca presents new data from sub-analysis of Phase III DAPA-HF trial » 10:08
03/28/20
03/28
10:08
03/28/20
10:08
AZN

AstraZeneca

$42.56 /

+0.26 (+0.61%)

New data from a…

New data from a sub-analysis of the landmark Phase III DAPA-HF trial showed that AstraZeneca's FARXIGA reduced the incidence of the primary composite endpoint of heart failure worsening or cardiovascular death compared to placebo, in patients with heart failure with reduced ejection fraction, irrespective of their background therapy. FARXIGA was evaluated in patients who were receiving a broad range of pharmacological treatments, device therapies and cardiac resynchronization therapy for HFrEF. A consistent reduction in the primary outcome was observed across all these treatment subgroups. FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D. In the US it is also approved to reduce the risk of hospitalization for HF in patients with T2D and established CV disease or multiple CV risk factors. In January 2020, the Food and Drug Administration accepted a supplemental New Drug Application and granted Priority Review for FARXIGA to reduce the risk of CV death or the worsening of HF in adults with HFrEF with and without T2D. The Prescription Drug User Fee Act date, the FDA action date for this supplemental application, is scheduled for the second quarter of 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion announces data presentations of NEXLETOL, NEXLIZET Tablet » 09:56
03/28/20
03/28
09:56
03/28/20
09:56
ESPR

Esperion

$35.28 /

-2.07 (-5.54%)

Esperion announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Orica upgraded to Buy from Sell at Goldman Sachs » 09:51
03/28/20
03/28
09:51
03/28/20
09:51
OCLDY

Orica

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Alex Karpos double upgraded Orica to Buy from Sell with a A$20.10 price target. The analyst is more positive on mine production versus "capex-tied earnings" in the current environment and views the recent selloff in the stock as an attractive entry point.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Goldman adds Austal to ANZ Conviction List with 31% potential upside » 09:48
03/28/20
03/28
09:48
03/28/20
09:48
AUTLF

Austal

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Alex Karpos added Austal to Goldman's ANZ Conviction List with 31% upside to the firm's unchanged price target of A$3.73. The analyst keeps a Buy rating on the shares. Austal is among the more defensive Australia Engineering & Construction stocks with minimal customer risk, long-duration earnings visibility, and a strong balance sheet, Karpos tells investors in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Redwood Trust delays payment for previously declared 32c dividend » 08:03
03/28/20
03/28
08:03
03/28/20
08:03
RWT

Redwood Trust

$6.22 /

+0.05 (+0.81%)

Redwood Trust announced…

Redwood Trust announced that it has delayed the payment date for its previously declared 32c per share common stock dividend for the first quarter of 2020. The first quarter 2020 dividend is now scheduled to be paid on June 12, 2020. As previously announced on February 27, 2020, the first quarter 2020 dividend will continue to be payable to stockholders of record on March 16, 2020. Christopher Abate, Chief Executive Officer of Redwood Trust, explained, "We remain focused on paying the first quarter dividend. While the decision to delay the payment of this dividend was difficult to make, we believe it is in the best interests of Redwood during this period of near-term uncertainty and volatility caused by the COVID-19 pandemic."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Merck, Intel among stocks multifactor-screened for extra safety, Barron's says » 07:23
03/28/20
03/28
07:23
03/28/20
07:23
CAT

Caterpillar

$105.20 /

-5.49 (-4.96%)

, MRK

Merck

$71.62 /

-1.77 (-2.41%)

, UNH

UnitedHealth

$241.80 /

-12.62 (-4.96%)

, INTC

Intel

$52.35 /

-3.26 (-5.86%)

, HON

Honeywell

$131.13 /

-6.095 (-4.44%)

, BBY

Best Buy

$62.36 /

-0.69 (-1.09%)

, GWW

Grainger

$246.57 /

+1.17 (+0.48%)

, DHI

D.R. Horton

$36.79 /

-2.58 (-6.55%)

, QCOM

Qualcomm

$66.50 /

-2.48 (-3.60%)

, AKAM

Akamai

$90.45 /

-4.05 (-4.29%)

, LMT

Lockheed Martin

$348.48 /

-1.96 (-0.56%)

, BLK

BlackRock

$434.59 /

-17.24 (-3.82%)

The financial markets are…

The financial markets are reeling and slammed by generational volatility, many stocks look like bargains, Al Root writes in this week's edition of Barron's. Picking winners and losers in this environment might feel like a fool's errand and starting to sort through the sea of opportunity is a wise idea, the author argues, adding that investors should embrace the power of the stock screen to find names with the right mix of factors for this moment. His final 12 include Caterpillar (CAT), Merck (MRK), UnitedHealth (UNH), Intel (INTC), Honeywell International (HON), Best Buy (BBY), W.W. Grainger (GWW), D.R. Horton (DHI), Qualcomm (QCOM), Akamai Technologies (AKAM), Lockheed Martin (LMT), and BlackRock (BLK). Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Still value in Softbank stock, Barron's says » 07:07
03/28/20
03/28
07:07
03/28/20
07:07
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

The coronavirus pandemic…

The coronavirus pandemic has further complicated matters for Softbank, pushing its market cap 70% below its asset value, and the company announced a plan to sell $41B of assets over the next 12 months and use $18B of the proceeds to buy back stock, on top of its existing $4.8B buyback, Eric Savitz writes in this week's edition of Barron's. At $35, Softbank's stock still sits at a 66% discount to its assets, the author notes, adding that the company has holdings worth almost triple its current stock price. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Apple, Amazon to come out of downturn strong, Barron's says » 07:02
03/28/20
03/28
07:02
03/28/20
07:02
GOOG

Alphabet

$1,110.80 /

-50.63 (-4.36%)

, GOOGL

Alphabet Class A

$1,109.46 /

-53.25 (-4.58%)

, AMZN

Amazon.com

$1,900.79 /

-52.4 (-2.68%)

, AAPL

Apple

$247.74 /

-10.74 (-4.16%)

, MSFT

Microsoft

$149.66 /

-6.35 (-4.07%)

Microsoft (MSFT), Apple…

Microsoft (MSFT), Apple (AAPL), Amazon.com (AMZN), and Google parent Alphabet (GOOGL) with their fortress-solid balance sheets, are poised to come out of the downturn just as strong as they went in, Eric Savitz writes in this week's edition of Barron's. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Week in Review: How Trump's policies moved stocks » 06:30
03/28/20
03/28
06:30
03/28/20
06:30
GM

General Motors

$21.37 /

-1.17 (-5.19%)

, F

Ford

$5.19 /

-0.07 (-1.33%)

, AAPL

Apple

$247.74 /

-10.74 (-4.16%)

, ADM

Archer Daniels

$33.52 /

-0.975 (-2.83%)

, GPP

Green Plains Partners

$7.10 /

+1.7 (+31.48%)

, BG

Bunge

$36.21 /

-1.59 (-4.21%)

, PEIX

Pacific Ethanol

$0.28 /

-0.0728 (-20.63%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Morgan Stanley wins antitrust approval for E-Trade acquisition, Bloomberg says » 18:54
03/27/20
03/27
18:54
03/27/20
18:54
MS

Morgan Stanley

$34.01 /

-1.67 (-4.68%)

, ETFC

E-Trade

$34.00 /

-1.77 (-4.95%)

Morgan Stanley (MS) won…

Morgan Stanley (MS) won U.S. antitrust approval for its $13B acquisition of E*Trade (ETFC), Bloomberg's David McLaughlin reports, citing a person familiar with the matter. The Justice Department's antitrust division has signed off on the takeover without requiring any changes, said the person, who asked not to be identified because the decision hasn't been made public. A Morgan Stanley spokesman declined to comment, the report added. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AG Mortgage disputes RBC's notices of events of default » 18:48
03/27/20
03/27
18:48
03/27/20
18:48
MITT

AG Mortgage

$4.02 /

-0.06 (-1.47%)

, RY

Royal Bank of Canada

$58.75 /

-2.72 (-4.42%)

On March 24, the company…

On March 24, the company received written notices from certain affiliates of Royal Bank of Canada alleging that events of default had occurred with respect to various financing agreements. The company disputes RBC's notices of events of default and filed a suit in federal district court in New York describing the wrongful conduct by RBC and seeking both to enjoin RBC from selling the company's collateral securities as well as damages. The company has also received notifications from several additional financing counterparties of alleged events of default under their financing agreements, and of certain of those counterparties' intentions to accelerate the company's and such subsidiaries' performance obligations under the relevant agreements. Under the terms of the applicable financing arrangements, if the company fails to deliver additional collateral or otherwise meet margin calls when due, the financing counterparties may demand immediate payment by the company of the aggregate outstanding financing obligations owed to such counterparties, and if such financing obligations are not paid, may sell the securities and apply the proceeds to the company's financing obligations and/or take ownership of the securities securing the company's financing obligations. The company may also be liable for a shortfall if the proceeds from such sale or value of such securities is less than the relevant financing obligation.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AG Mortgage continues discussions with counterparties on forbearance agreements » 18:44
03/27/20
03/27
18:44
03/27/20
18:44
MITT

AG Mortgage

$4.02 /

-0.06 (-1.47%)

Since March 23, the…

Since March 23, the company and several of its subsidiaries have received notifications from several financing counterparties of alleged events of default under their financing agreements, and of certain of those counterparties' intentions to accelerate the company's and such subsidiaries' performance obligations under the relevant agreements. The company and its subsidiaries have disputed certain of those notices. However, in the event of a default under one or more of those agreements, financial and other obligations under such agreements, and in some cases the company's obligations as a guarantor, may be accelerated and the counterparties may take ownership of the securities pledged to secure the financing obligations by the company or its subsidiaries. Certain counterparties have informed the company that they have sold the securities pledged to secure the financing obligations. The company and its subsidiaries also may be subject to penalties under those agreements and may suffer cross-default claims from its other lenders. The company continues to engage in discussions with its financing counterparties with regard to entering into forbearance agreements pursuant to which each counterparty would agree to forbear from exercising its rights and remedies with respect to an event of default under the applicable financing arrangement for an agreed-upon period. The company cannot predict whether its financing counterparties will enter into a forbearance agreement, the timing of any such agreement, or the terms thereof.

Hot Stocks
AG Mortgage suspends dividends » 18:41
03/27/20
03/27
18:41
03/27/20
18:41
MITT

AG Mortgage

$4.02 /

-0.06 (-1.47%)

On March 27, the company…

On March 27, the company announced that the Board has approved a suspension of the company's quarterly dividends on the company's common stock, the company's 8.25% Series A Cumulative Redeemable Preferred Stock, the company's 8.00% Series B Cumulative Redeemable Preferred Stock, and the company's 8.000% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock, beginning with the common dividends that normally would have been declared in March and the preferred dividends that would have been declared in May. The Board's decision reflects the company's continuing focus on conserving capital and improving its liquidity position during the current market volatility.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.